Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE – Reduced Immunosuppression With Once-Daily Tacrolimus in Elderly Kidney Transplant Recipients
2014-002643-18Phase 4Active
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- May 2018
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of tacrolimus in kidney allograft rejection (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Combined efficacy endpoint. Started May 2018; status: active.
02
Drugs
tacrolimus
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2014-002643-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002643-18.